AITRICS to Report the Results of Clinical Trials of 'VitalCare' to the MFDS

2022.08.02

Proving its Predictice Performance in Sepsis, Death, and ICU for the First Time in Korea Targeting to enter the market in the second half of 2022 [August 2, 2022] AITRICS (CEO Kwang joon Kim, Jin-gyu Yoo), a company specializing in artificial intelligence (AI) technology, announced on the 2nd that it reported the results of three confirmed clinical trials of VitalCare which is a solution for predicting patient condition changes. VitalCare is an artificial intelligence (AI) monitoring solution by AITIRCS that predicts the risk of acute events in the ward based on a total of 19 levels, including bio-signals and hematological tests collected from electronic medical records (EMR), and provides 0-100 points of certainty. The three clinical trials were conducted on a total of 7,375 patients who were hospitalized to the National Health Insurance Corporation Ilsan Hospital as a single institution, single group, and retrospective test to evaluate the efficacy of VitalCare. According to the results of three clinical trials, the predictive accuracy of the acute severe event*, sepsis, and acute exacerbation (AUROC: Area Under ROC Curve) was 0.96, 0.87, and 0.98, respectively, which was higher than the existing medical score. In particular, VitalCare proved its predictive performance in sepsis, death, and ICU for the first time in Korea, and based on the results of this clinical trial, AITRICS is expected to speed up the approval of VitalCare in Korea within this year. Soo-ji Lee, Lead of AITRICS's RA/QA team said "We are happy to be able to confirm the performance of VitalCare in various indications through three confirmed clinical trials conducted at the same time. We expect Vitalcare to improve the possibility of treatment and work efficiency of medical staff in clinical practice and to provide improved medical services to patients". And she added, "AITRICS is currently undergoing simultaneous evaluation of the approval of MFDS, reimbursement, and new health technology assessment based on excellent study, and is expected to enter the market in the second half of this year." Meahwhile, AITRICS has proven the clinical value of VitalCare as an excellent tool for predicting changes in patient's acute condition in research published in JMIR, one of the world's top medical information journals, and Clinical Care. In addition, various international AI conferences such as NeurIPS and ICML have achieved remarkable excellent results every year and are recognized worldwide for their technical skills. * Acute severe event: 1) Acute severe event in general ward within 6 hours (death, unexpected total chamber, cardiac arrest) 2) Sepsis in general ward within 4 hours 3) Acute deterioration in intensive care unit within 6 hours (death)